The effects of luteolin on the proliferation of A549 cells were evaluated by MTT and clone formation assays. DNA ploidy and apoptotic cell percentage were calculated by flow cytometry. The expression of Bax, Bcl-xl, Bcl-2, Mcl-1, caspase-9, caspase-3, and PARP was analyzed by Western blotting. The membrane potential of mitochondria was detected by JC-1 fluorescence microscopy assay. Our results demonstrated that luteolin could inhibit the proliferation of A549 cells via induction of apoptosis, with the evidence of characteristic morphological changes of apoptosis in the nucleus. Furthermore, DNA flow cytometric analysis indicated that luteolin induced a S phase arrest of the cell cycle. The membrane potential of mitochondria was decreased. The protein levels of Bax, Bcl-xl, Bcl-2, Mcl-1, caspase-9, caspase-3, and PARP were activated after treatment with luteolin. Luteolin can inhibit the proliferation of A549 cells and trigger mitochondria-dependent apoptosis in them.
Lung cancer is the leading cause of death from malignancies worldwide [1a,1b] . It is classified histologically into small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The standard therapeutic strategy for advanced NSCLC is platinumbased double-agent chemotherapy, which, however, has reached a plateau of potency in improving survival of patients [1c,1d] . Only a few ''target agents'' have shown benefits when used in combination with platinum-based double-agent for NSCLC chemotherapy, such as bevacizumab, erlotinib and gefitinib [1e,1f] . Various novel therapeutic strategies are currently under consideration, as the clinical use of cytotoxic drugs is limited due to either intrinsic or acquired resistant and toxicity. Therefore, the development of new chemotherapeutic agents and combination regimens against NSCLC is desired. At the molecular level, luteolin (3′,4′,5,7-tetrahydroxyflavone, LT) has been reported to modulate a number of key elements in cellular signal transduction pathways linked to the apoptotic process (caspases and Bcl-2 genes), but that regulation and induction of apoptosis are unclear. The aim of the present investigation was to provide insights into the molecular basis of the chemopreventive activities of luteolin, with emphasis on its ability to control intracellular signaling cascades responsible for regulating apoptosis, a relevant target in a cancer-preventive approach.
Luteolin inhibits the growth of A549 cell lines: MTT assay was used to determine the effect of luteolin on A549, L-02, and Panc-1 cell proliferation. A549, L-02 and Panc-1 cells were exposed to various concentrations of luteolin for 48 hours. As shown in Figure  1A , exposure to luteolin resulted in dose-dependent inhibition of cell viability. However, the drug had little cytotoxicity to L-02 cells, the normal hepatic cell. The IC 50 value for the A549 and Panc-1 cells was 80.0μM, 75.0μM respectively (P<0.05 vs control group). Colony formation assay also showed that luteolin strongly inhibited the proliferation of A549 and Panc-1 cells ( Figure 1B) . Luteolin arrests the cell cycle progression in A549 cells and promotes apoptosis: To study the molecular mechanism by which luteolin inhibits the proliferation of A549 cells, we used FCM to analyze the effects of the compound on cell cycle progression and apoptosis, The results showed that the cell cycle progression was significantly inhibited in the S phase (Figure 2A ), and apoptosis rates increased significantly after treatment with luteolin. Annexin V assay showed early apoptosis induced by luteolin in A549 ( Figure  2B ); the percentage of Annexin V-positive/ PI-negative A549 cells was increased from 4.3% to 36.6% after treatment with increasing concentration of luteolin.
Luteolin changes the protein expression levels of Bcl-2 family numbers: To study the mechanism by which luteolin inhibits cell cycle progression and induces cell apoptosis, A549 cells were used for protein expression analysis. Since the intrinsic pathway of apoptosis is regulated by Bcl-2 family member proteins, these were analyzed as target proteins by Western blot. The results showed that the protein expression levels of Bax increased significantly after treatment with luteolin, The protein expression levels of Bcl-2 and Bcl-xl also decreased, while that of Mcl-1 (Figure 3) was not affected. Together, these results imply that luteolin induced cell apoptosis through activation of the Bcl-2 family member proteins. As a result of these changes, the ratios of Bcl-2/Bax, Mcl-1/Bax and Bcl-xl/Bax reduced significantly.
Luteolin changes membrane potential of mitochondria and activates caspases-3/9/PARP in A549 cells: To investigate the roles of caspases in luteolin-induced apoptosis, we determined the activation of caspase-3 and caspase-9 in A549 cells treated with different concentrations of luteolin for 48 h. The results showed that luteolin activated caspase-9 and caspase-3 in a dose-dependent manner ( Figure 4A ). The membrane potential of mitochondria in A549 cells was tested after luteolin treatment. For the cytofluorimetric analysis of mitochondrial membrane potential in intact cells the lipophilic cationic probe 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1) was used. The JC-1 monomer emits at 527 nm after excitation at 490 nm. Depending on the membrane potential, JC-1 is able to form J-aggregates that are associated with a large shift in emission (590 nm). The color of the dye changes reversibly from green to greenish orange as the mitochondrial membrane becomes more polarized. Figure 4B shows that the orange was reduced in A549 cells treated with DMSO and 60 μmol/L of luteolin for 48 h compared with the control groups.
Our study was carried out to elucidate the apoptotic mechanism of luteolin in A549 cells. Luteolin exerted antiproliferative activity in A549 cells with an IC 50 of 80 μM, as seen by MTT assay. In addition, flow cytometric analysis showed that luteolin can increase the sub S portion in A549 cells, suggesting apoptosis. Similarly, the increase in membrane alteration in cells positively stained by Annexin V implies the early stages of apoptosis of A549 cells. These data suggest that the antiproliferative effect of luteolin in A549 cells is due to apoptosis.
There are three known ways to induce apoptosis: the death receptor pathway, the mitochondrial pathway, and endoplasmic reticulum stress-induced apoptosis. The mitochondrial pathway is the one which has been relatively well studied and understood. The Bcl-2 family is the key regulator of the mitochondrial pathway, which includes anti-and pro-apoptotic members [2a,2b] . Our research shows that, after luteolin treatment, the protein expression levels of
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Bcl-xl, Bcl-2 and Mcl-1 (Bcl-2 anti-apoptotic members) changed, which suggests that luteolin might induce apoptosis by decreasing the expression levels of Bcl-2 anti-apoptotic members, such as Bclxl, Bcl-2 and Mcl-1. Bcl-2 is localized in the mitochondria, endoplasmic reticulum, and nuclear membranes. The increase in the Bax/Bcl-2 ratio could induce cell apoptosis [3a-3c] . Treatment of A549 cells with luteolin decreased Bcl-2 and increased Bax protein expression levels.
In this study, luteolin effectively activated the expression of caspase 9 and 3, and cleaved poly (ADP-ribose) polymerase (PARP). In addition, the reduction of mitochondrial membrane potential by luteolin established that the mitochondrial pathway was involved in luteolin-induced apoptosis [3d] . Accumulating evidence indicates that mitochondria play a pivotal role in the apoptotic process in A549 cells [4a] . Disruption of mitochondrial ΔΨm is considered to be an indicator of mitochondrial damage and generally is defined as an early stage of apoptosis, preceding efflux of small molecules from the mitochondria (including cytochrome c, apoptosis-inducing factor), and followed by caspase-9/caspase-3 cascade activation [4b,4c] . In the present study, we found a marked activation of caspases (caspase-3, and -9) by luteolin after the breakdown of ΔΨm, suggesting that mitochondria-mediated pathway is involved in luteolin-triggered apoptosis. Luteolin examined in this study possessed common effects, the induction of apoptosis involving the breakdown of ΔΨm, activation of caspases and down-regulation or up-regulation of Bcl-2 family members, and also induction of cell cycle arrest. Moreover, examples of interaction between polyphenols and/or conventional synthetic drugs used in cancer treatment have been described, providing an interesting approach to combination therapy. However, because of the complexity and interrelationships of transduction pathways, the mechanisms for inducing the apoptosis of these polyphenols may overlap with other signaling cascades; thus, programmed cell death can be promoted through the modulation of different proteins in other pathways that can contribute to cell death.
Although results from in vitro experiments cannot be directly extrapolated to clinical effects, they constitute a valuable tool for elucidating the pathways involved in the overall carcinogenesis process. More studies are needed to clearly understand the mechanisms of action of flavonoids as modulators of cell apoptosis, which is crucial for the evaluation of their potential as anticancer agents.
Experimental
Cells and materials: A549 (human lung adenocarcinoma cells), Panc-1 (human pancreatic carcinoma cells), and L-02 (human normal liver cells) were obtained from Zhongshan University (Guangzhou, China) and were maintained in RPMI 1640 (Gibco Corporation, Carlsbad, California, USA) supplemented with 10% new born bovine serum at 37°C and 5% CO 2 . Luteolin (Sigma, USA) was solubilized in dimethylsulfoxide (DMSO) and the concentration adjusted to 2400 μmol/L, as stock solution. The final concentration of DMSO in the culture medium did not exceed 0.1%.
Cell proliferation assay:
Cell proliferation was evaluated by the MTT assay. In brief, exponentially growing A549 cells were seeded into 96-well culture plates at a density of 5×10 3 cells/well and allowed to adhere overnight. Cells were incubated with various concentrations of drugs for 48 h. MTT solution (5.0 mg/mL in RPIM-1640) was added (20.0 μL/well), and plates were incubated for a further 4 h at 37°C. At the end of the incubation period, the purple formazan crystals were dissolved in 150 μL DMSO. After the crystals had dissolved, the plates were read on an automated microplate spectrophotometer (Thermo Electron Corporation) at 570 nm. The inhibition rate of cell proliferation was calculated for each well as (A570 control cells -A570 treated cells）/A570 control cells ×100%. The IC 50 values were determined by the Logit method.
Clone formation assay: A549 cells and Panc-1 were cultured in 12-well microplates (400 cells /well) in 2 mL of complete RPMI 1640 for 12 h, then treated with the indicated concentrations of luteolin for 7 day. Cells were stained with crystal violet for 20 min and photographed.
Cell cycle analysis: A549 cells were collected by centrifugation after treatment with luteolin, then washed with PBS, and fixed with ice-cold 70% ethanol. The fixed cells were harvested by centrifugation at 1000 rpm for 5 min and resuspended in 500 μL of PBS, then treated with RNase A (100 μg/mL, 30 min, 37°C). After incubation, the cells were stained with 10.0 μg/mL propidium iodide at 37°C for 30 min. The fluorescence of the cells was analyzed with a FACS-Calibur flow cytometer in the dark.
Cell apoptosis and death analysis: A549 cells in exponential growth were treated with different concentrations of luteolin 20, 40, 60 and 80 μmol/L) for 48 h. Assessment of apoptotic and dead cells was carried out by Annexin V and propidium iodide staining. After incubation, cells were washed twice with PBS, and the cell pellet was resuspended with Annexin V binding buffer, followed by incubation with Annexin V conjugated to FITC (BD PharMingen) and propidium iodide staining solution (BD PharMingen) for 5 min at room temperature in the dark. Cells were then analyzed by flow cytometry as soon as possible (within 1 h).
Measurement of the mitochondrial membrane potential (ΔΨm):
JC-1 (Sigma,USA) was used to measure the ΔΨm, as described previously [5a-5c] . A549 cells (1.5×105/mL) were treated with different concentrations of luteolin for 48 h. ΔΨm was measured by JC-1 dye, in which mitochondria depolarization is indicated by a switch from red to green fluorescence intensity. Pictures were taken under a fluorescent microscope.
Western blotting analysis: A549 cells were treated with DMSO, 20, 40, and 60 μmol/L of luteolin for 48 h. Whole cell lysates were prepared by adding 5×SDS sample buffer. Equal amounts of protein were electrophoresed on 12% SDS-PAGE gels and transferred to PVDF membranes. The membranes were then blocked for 60 min at room temperature with 5% nonfat dry milk/TBST (TBS-Tween 20) and reacted with appropriate antibodies for Bax; Bcl-xl; Bcl-2; Mcl-1; caspase-9; caspase-3; and PARP (Cell Signaling, Danvers, Massachusetts, USA) overnight at 4°C. Following incubation with the primary antibody, membranes were washed in TBST and incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. Proteins were visualized by incubation with SuperSignal west pico reagents (NCI5079 Thermo), followed by exposure to radiograph film.
Statistical analysis:
All assays were performed in triplicate. Statistical analysis was performed using analysis of variance with SPSS 13.0 software.
